Single Use Downstream Bioprocessing Market

Market Size

The global single use downstream bioprocessing market, valued at USD 3.78 billion in 2025, is projected to reach USD 4.21 billion in 2026 and USD 12.15 billion by 2035, with a 12.5% CAGR during the forecast period 2026 to 2035.

Market Report: Key Takeaways

• The growing demand for biologics, cell and gene therapies, and advanced therapies is driving the need for advanced manufacturing technologies that offer higher yields and greater scalability, ensuring that complex therapeutics can be produced efficiently at a commercial scale.
• In terms of type of product, single use chromatography systems and single use filtration systems dominate (>60%) the market as chromatography and filtration are the primary step responsible for removing impurities in downstream processing and plug-and-play assemblies effectively reduce facility turnaround times while maintaining the sterile integrity required for complex biologics.
• With respect to the scale of operation, commercial scale currently holds around 80% of the market share. This single use downstream bioprocessing market trends is driven by the transition of drug candidates from clinical to commercial stages, which demands high-volume manufacturing to meet global patient needs.

• In terms of sub-categories of end users, the pharma and biopharmaceutical companies are contributing to the overall market size as these companies are the primary developers of high-volume biologics like monoclonal antibodies and recombinant proteins.
• In terms of geographical regions, currently Europe holds around 35% of the single use downstream bioprocessing market share.

Market Overview

Single use downstream bioprocessing systems are revolutionizing drug manufacturing, allowing pharmaceutical companies and CDMOs to flexibly scale out, scale up, or scale down in response to fluctuating production volumes. Further, these systems minimize downtime for cleaning, sterilization, maintenance, and process customization while eliminating energy-intensive steps like clean-in-place (CIP) and steam-in-place (SIP) validation. Key innovations include pre-packed chromatography columns, tangential flow filtration assemblies, and disposable membrane adsorbers.

The adoption of single use technology in biopharmaceutical manufacturing has grown steadily increasing, with downstream bioprocessing witnessing a remarkable increase in the last few years. Compared to traditional stainless-steel systems, single use technologies for downstream bioprocessing offer various advantages, such as lower capital expenditure, faster facility design and commissioning, reduced project lead times (by up to 8 months), and greater agility for rapid scale-up and customization.

Consequently, in-house manufacturers and contract development and manufacturing organizations are increasingly adopting these single use systems to handle smaller, personalized batch sizes and frequent product changeovers. Driven by this increasing adoption and ongoing efforts to enhance equipment capabilities, we expect that single use downstream bioprocessing market growth will maintain a robust upward trajectory.

Reshaping Biopharmaceutical Purification via High-Throughput Membrane Adsorbers and Pre-Packed Columns

Accelerating Downstream Workflows with Ready-to-Process Chromatography Solutions

The shift toward single use chromatography is redefining the economics of downstream processing by replacing labor-intensive column packing with pre-packed, pre-validated disposable columns and membrane adsorbers. This transition addresses the industry's critical need to eliminate cross-contamination risks and reduce the heavy footprint of cleaning validation associated with traditional stainless-steel skids. Moreover, modern membrane adsorbers offer significantly higher flow rates than conventional resins, are now becoming standard for flow-through polishing, enabling rapid virus removal and DNA impurity removal without diffusive mass transfer bottlenecks.

These advancements boost flexibility of multi-product facilities, allowing manufacturers to switch between different monoclonal antibodies or viral vectors in days rather than weeks. Further, the integration of smart columns tagged with RFID ensures automated tracking of cycle-count and resin-history, ensuring seamless regulatory compliance while maximizing the utilization of expensive purification media before disposal.

Advancing Concentration Management with Automated Single Use Tangential Flow Filtration (TFF)

Optimizing Product Recovery with Intelligent Single Use Filtration Platforms

The single use tangential flow filtration market has evolved from manual, open operations to fully automated, closed operations. Advanced single use sensors, integrated directly into the flow path, enable precise control of transmembrane pressure (TMP) and flow, minimizing filter fouling during concentration of high-viscosity biologics.

To meet the demand for high-concentration formulations, innovative single use filter capsules offer scalable designs that deliver linear performance from bench-top to commercial scale. These solutions streamline complex diafiltration, maximize product recovery, and shield operators from exposure to potent drug substances (a critical requirement in the booming antibody drug conjugate market).

Market Drivers

• Rising Pipeline of Biologics, Injectables and Complex Therapies: The growing demand for biologics, vaccines and advanced therapeutics is driving the need for flexible downstream processing technologies. Downstream purification steps, such as filtration, chromatography, and aseptic sampling are increasingly adopting single use formats to support faster changeovers, higher purity, and lower contamination risks compared to traditional stainless-steel systems. Further, single use chromatography columns and disposable filters allow manufacturers to handle complex biomolecules with reduced process risk and enhanced product quality. Owing to these advantages, adoption of disposable technologies in downstream workflows is expected to increase over the coming years.
• Growing Shift Towards Sustainable and Cost-Efficient Manufacturing: In recent years, the biopharma sector has intensified its focus on minimizing both the environmental footprint and operational expenses (OPEX). Companies are exhibiting a growing preference for single use technology that offers substantial reductions in upfront capital investment and reduces the lead time compared to conventional facilities. These advantages have made single use systems a standard for accelerating development efforts and time-to-market for new therapies.

Industry Experts on Single Use Downstream Bioprocessing Market Report

Discussions of multiple stakeholders in this domain influenced the opinions and insights presented in this study.

Ralph Daumke (Market Manager, Pendotech), stated that, “The market is shifting from a hype phase to normalization. The hype was largely based on the COVID-19 pandemic, which turned out to be a boost for the industry due to the unprecedented global demand for vaccines. Due to uncertainty caused by disrupted supply chains and a scarcity of single-use equipment, everyone tried to stack up on scarce products in order to avoid production standstills.”

Market Segmentation Analysis

Single Use Downstream Bioprocessing Market Analysis by Scale of Operation: Commercial Segment Holds the Largest Market Share

• The global market is segmented across different scales of operation, such as preclinical and clinical, and commercial. The commercial sub-segment occupies the largest (85%) single use downstream bioprocessing market size in 2035.
• This dominance stems from the shift to the continuous manufacturing of approved drug to meet the surging commercial demand. As therapies gain regulatory approval, production scales up from small investigative batches to large-scale production, boosting demand for single use consumables and solidifying commercial segment dominance.

Market Regional Insights

Europe Dominates the Current Single Use Downstream Bioprocessing Industry

Europe dominates the market, capturing approximately 35% of the overall revenue share. This is due to the mature biopharmaceutical manufacturing infrastructure and a pioneering regulatory framework within the region. Notably, the presence of major industry players in European countries, such as Germany and France, specifically Sartorius Stedim Biotech and Merck, who have established robust regional manufacturing hubs and integrated single use platforms to standardize these formats across the global supply chain, have further contributed to the region’s dominance.

Single Use Downstream Bioprocessing Market: Scope of the Report

Market Segments

Based on the research, we have segmented the Single Use Downstream Bioprocessing Market into type of product, scale of operation, end user and geographical regions

By Type of Product

• Single Use Chromatography Systems
• Single Use Filtration Systems
• Single Use Connectors
• Single Use Sampling Systems
• Single Use Centrifugation Systems
• Other Single Use Systems

By Scale of Operation

• Preclinical and Clinical
• Commercial

By End User

• Pharma and Biopharmaceutical Companies
• CROs and CMOs
• Other End Users

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Frequently Asked Questions